PURPOSE: The prognostic significance of age at testicular cancer (TC) diagnosis, socioeconomic status (SES), race, and marital status on TC-specific mortality is not well-characterized. In a cancer that is so curable, it is important to identify any influence that confers an increased risk of TC-specific mortality. PATIENTS AND METHODS: Using multivariate cause-specific Cox regression models that accounted for competing risks, hazard ratios (HRs) were calculated for 10-year TC-specific mortality among 27,948 patients with TC reported to the Surveillance, Epidemiology and End Results program (1978 to 2006). Independent predictors were age at diagnosis, SES, race, marital status, extent of disease (EOD), calendar year of diagnosis, radiotherapy, and retroperitoneal lymph node dissection (RPLND). RESULTS: Compared with younger patients, diagnostic age 40+ was associated with increased mortality (seminoma, HR, 2.00, P < .001; nonseminoma, HR, 2.09; P < .001; most evident in metastatic disease, HR, 8.62; P < .001; HR, 6.35; P < .001, respectively). Unmarried men had two-to three-fold excess mortality compared to married men (HR, 2.97; P < .001; HR, 1.54; P < .001, respectively). Among nonseminoma patients, decreasing SES (P trend < .001) and nonwhite race (HR, 2.11; P < .001) increased mortality. Diagnosis after 1987 resulted in reduced mortality compared to earlier calendar years (HR, 0.58; P = .001; HR, 0.74; P = .001, respectively). Lack of RPLND was associated with seven-fold increase in death (P < .001). CONCLUSION: TC-specific mortality is doubled among US patients diagnosed with seminoma or nonseminoma after age 40, even when initial treatment and EOD are taken into account. Among men with nonseminoma, nonwhite race and lower SES also significantly increase TC-specific mortality. Additional research is needed, enabling the development of interventional strategies and preventive approaches, as applicable.
PURPOSE: The prognostic significance of age at testicular cancer (TC) diagnosis, socioeconomic status (SES), race, and marital status on TC-specific mortality is not well-characterized. In a cancer that is so curable, it is important to identify any influence that confers an increased risk of TC-specific mortality. PATIENTS AND METHODS: Using multivariate cause-specific Cox regression models that accounted for competing risks, hazard ratios (HRs) were calculated for 10-year TC-specific mortality among 27,948 patients with TC reported to the Surveillance, Epidemiology and End Results program (1978 to 2006). Independent predictors were age at diagnosis, SES, race, marital status, extent of disease (EOD), calendar year of diagnosis, radiotherapy, and retroperitoneal lymph node dissection (RPLND). RESULTS: Compared with younger patients, diagnostic age 40+ was associated with increased mortality (seminoma, HR, 2.00, P < .001; nonseminoma, HR, 2.09; P < .001; most evident in metastatic disease, HR, 8.62; P < .001; HR, 6.35; P < .001, respectively). Unmarried men had two-to three-fold excess mortality compared to married men (HR, 2.97; P < .001; HR, 1.54; P < .001, respectively). Among nonseminoma patients, decreasing SES (P trend < .001) and nonwhite race (HR, 2.11; P < .001) increased mortality. Diagnosis after 1987 resulted in reduced mortality compared to earlier calendar years (HR, 0.58; P = .001; HR, 0.74; P = .001, respectively). Lack of RPLND was associated with seven-fold increase in death (P < .001). CONCLUSION: TC-specific mortality is doubled among US patients diagnosed with seminoma or nonseminoma after age 40, even when initial treatment and EOD are taken into account. Among men with nonseminoma, nonwhite race and lower SES also significantly increase TC-specific mortality. Additional research is needed, enabling the development of interventional strategies and preventive approaches, as applicable.
Authors: Christina L Roland; Aihua Bian; John C Mansour; Adam C Yopp; Glen C Balch; Rohit Sharma; Xian-Jin Xie; Roderich E Schwarz Journal: J Surg Oncol Date: 2011-10-17 Impact factor: 3.454
Authors: Julia H Rowland; Erin E Kent; Laura P Forsythe; Jon Håvard Loge; Lars Hjorth; Adam Glaser; Vittorio Mattioli; Sophie D Fosså Journal: Cancer Date: 2013-06-01 Impact factor: 6.860
Authors: Giuseppe Rosiello; Sophie Knipper; Carlotta Palumbo; Cristina Dzyuba-Negrean; Angela Pecoraro; Elio Mazzone; Francesco A Mistretta; Zhe Tian; Umberto Capitanio; Francesco Montorsi; Shahrokh F Shariat; Fred Saad; Alberto Briganti; Pierre I Karakiewicz Journal: Int Urol Nephrol Date: 2019-08-29 Impact factor: 2.370
Authors: Chunkit Fung; Howard D Sesso; Annalynn M Williams; Sarah L Kerns; Patrick Monahan; Mohammad Abu Zaid; Darren R Feldman; Robert J Hamilton; David J Vaughn; Clair J Beard; Christian K Kollmannsberger; Ryan Cook; Sandra Althouse; Shirin Ardeshir-Rouhani-Fard; Steve E Lipshultz; Lawrence H Einhorn; Sophie D Fossa; Lois B Travis Journal: J Clin Oncol Date: 2017-02-27 Impact factor: 44.544
Authors: A Stang; L Jansen; B Trabert; C Rusner; A Eberle; A Katalinic; K Emrich; B Holleczek; H Brenner Journal: Cancer Epidemiol Date: 2013-04-23 Impact factor: 2.984
Authors: Solomon L Woldu; Joseph A Moore; Bo Ci; Yuval Freifeld; Timothy N Clinton; Ahmet M Aydin; Nirmish Singla; Krabbe Laura-Maria; Ryan C Hutchinson; James F Amatruda; Arthur Sagalowsky; Yair Lotan; Yull Arriaga; Vitaly Margulis; Yang Xie; Aditya Bagrodia Journal: Eur Urol Oncol Date: 2018-06-06